Morten Helms
Overview
Explore the profile of Morten Helms including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
576
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ellegaard Paaske S, Baumwall S, Rubak T, Birn F, Ragard N, Kelsen J, et al.
Clin Gastroenterol Hepatol
. 2024 Jun;
23(4):602-611.e8.
PMID: 38871148
Background & Aims: Clostridioides difficile infection (CDI) is associated with high mortality. Fecal microbiota transplantation (FMT) is an established treatment for recurrent CDI, but its use for first or second...
2.
Holmstroem R, Dahl E, Helms M, Nielsen H, Andersen J, Bjerrum J, et al.
BMJ Open Gastroenterol
. 2022 Dec;
9(1).
PMID: 36581371
Background: Immune checkpoint inhibitors (ICIs) can induce a wide range of immune-related adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently reported irAE, whereas enteritis is rare...
3.
Svensson C, Cold F, Ribberholt I, Zangenberg M, Mirsepasi-Lauridsen H, Petersen A, et al.
Cells
. 2022 Oct;
11(20).
PMID: 36291139
The most effective treatment for recurrent infection (CDI) is faecal microbiota transplantation (FMT); however, the optimal route of administration is thus far unknown. This retrospective cohort study of 343 patients...
4.
Rubin I, Mollerup S, Broholm C, Knudsen S, Baker A, Helms M, et al.
Microbiol Spectr
. 2022 Apr;
10(3):e0234821.
PMID: 35475684
The purpose of this trial was to evaluate the efficacy of a 4-week supplementation of Lactobacillus rhamnosus GG (LGG) in eliminating the gastrointestinal carrier state of vancomycin-resistant Enterococcus faecium (VREfm)...
5.
Cold F, Svensson C, Petersen A, Hansen L, Helms M
Cells
. 2022 Feb;
11(3).
PMID: 35159245
Faecal microbiota transplantation (FMT) is the recommended treatment for recurrent infection (rCDI) following a second recurrence. FMT is considered safe in the short term when procedures for the screening of...
6.
Cold F, Svensson C, Hojer Christensen A, Gunther S, Petersen A, Hansen L, et al.
Dan Med J
. 2022 Jan;
69(2).
PMID: 35088703
Introduction: Treatment of recurrent Clostridioides difficile infection with faecal microbiota transplantation (FMT) is highly effective and is the recommended treatment following a second recurrence. The cure rates of capsule treatment...
7.
Dahl Baunwall S, Terveer E, Frederik Dahlerup J, Erikstrup C, Arkkila P, Vehreschild M, et al.
Lancet Reg Health Eur
. 2021 Oct;
9:100181.
PMID: 34693388
Background: Faecal microbiota transplantation (FMT) is an emerging treatment modality, but its current clinical use and organisation are unknown. We aimed to describe the clinical use, conduct, and potential for...
8.
Dahl Baunwall S, Frederik Dahlerup J, Engberg J, Erikstrup C, Helms M, Juel M, et al.
Scand J Gastroenterol
. 2021 Jul;
56(9):1056-1077.
PMID: 34261379
This Danish national guideline describes the treatment of adult patients with Clostridioides (formerly Clostridium) difficile (CD) infection and the use of faecal microbiota transplantation (FMT). It suggests minimum standard for...
9.
Rode A, Chehri M, Krogsgaard L, Heno K, Tolboll Svendsen A, Ribberholt I, et al.
Aliment Pharmacol Ther
. 2021 Mar;
53(9):999-1009.
PMID: 33694229
Background: A defined bacterial mixture could be a safer alternative to faecal microbiota transplantation (FMT). Aims: To compare the efficacy of a 12-strain mixture termed rectal bacteriotherapy with either FMT...
10.
Rasmussen L, Schultz M, Iversen K, Eugen-Olsen J, Helms M, David K, et al.
Clin Biochem
. 2020 Jun;
84:31-37.
PMID: 32504704
Background: Accurate first-line diagnostics are essential for early recognition of cancer but also to identify patients free of disease. The biomarker soluble urokinase plasminogen activator receptor (suPAR) is elevated in...